EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Michel Toungouz

Work experience

-Clinical Assessor and scientific expert ATMP (FAMHP / Sciensano, Belgium, since 01/2025)
-Councillor (Solidaris, Belgium, 8/2024 – 12/2024)
-CEO (Laboratoire National de Santé, Luxembourg, 1/2/2024 – 2/4/2024)
-Cryopreservation lead and responsible person (Johnson &Johnson, Belgium, 5/2023 - 9/2023)
-Medical Director (University Hospital Laboratory of Brussels, Belgium, 5/2022-2/2023)
-Deputy CEO (French speaking Blood Services, Belgian Red Cross, Belgium, 3/2020-5/2022)
-Head of the Center of Tissue and Cell Therapy (Cliniques Saint-Luc, Belgium, 6/2016-3/2020)
-Head of clinic Hematology-Transfusion (Erasme Hospital, Belgium, 1/2005-6/2016)
-Deputy Head of clinic at the department of immunology-hematology-transfusion (Erasme Hospital, Belgium, 11/1999-1/2005)
-Post-doctoral fellow (FNRS , Belgium, 11/1998-11/1999)
-Research fellow (FNRS, Belgium, 10/1994-10/1998)
-Research fellow Fonds Erasme (Erasme Hospital, Belgium,10/1993-10/1994)
-Trainee in laboratory medicine (Erasme Hospital, Belgium, 10/1989-9/1993)

Education and training

-University Degree in transfusion medicine (Université Paris VI, France, 6/1995 - 6/1997)
-PhD in Immunology (Université Libre de Bruxelles, Belgium, 10/1992 - 4/1996)
-Specialist in Laboratory Medicine (Université Libre de Bruxelles, Belgium, 9/1989 - 9/1995)
-Medical Doctor (Université Libre de Bruxelles, Belgium, 9/1982 - 6/1989)

Additional information

Publications

1. Differential inducibility of HLA Class I and II antigens by rIFN- in type III bare lymphocyte syndrome. M. Andrien, P. Stordeur, E. Vamos, F. Mascart-Lemone, M. Toungouz, G. Monfils, E. Dupont. Transpl Proc, 23, 1991:441
2. Immunological selection of bone marrow donors. M. Toungouz-Nevessignsky, M. Andrien, E. Dupont. Rev Med Brux, 13, 1993:300-1.
3. Alloactivation induced during MLR by HLA class II differences provokes release by macrophages of tumor necrosis factor-a and interleukin-6 and primes them to lipopolysaccharides. M.Toungouz., C.

Denys , D. De Groote, M. Andrien, E. Dupont. Hum Immunol, 38, 1993: 221-225

4. Effects of two different dosages of aprotinin on perioperative blood loss during liver transplantation. B. Ickx, O. Pradier, F. Degroote, C. Hendrice, M. Toungouz, Vandestadt J., Gelin M. and P. Capel. Seminars in thrombosis and hemostasis, 19, 1993:300-301
5. HLA-B locus DNA typing: Detection of B*7801 and seven additional alleles by Bw6-specific exon 2 amplification. M. Andrien, J.-M. Tiercy , V. Defleur, C. Bouillenne, M. Toungouz, M. Jeannet and E. Dupont. Tissue Antigens, 42, 1993: 480-487
6. Tumor necrosis factor-α and interleukin-6 production induced by variations of DR4 polymorphism during the primary mixed lymphocyte reaction. M. Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. Transplantation, 58, 1994: 1393-1398
7. HLA-DR subtypes induce IL-6 and TNF-α production in primary mixed lymphocyte reaction. M. Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. Transpl Proc, 27, 1995: 461-462
8. In vitro inhibition of tumor necrosis factor-α and interleukin-6 production by intravenous immunoglobulins. M. Toungouz, C. Denys, D. De Groote, E. Dupont. Brit J Haematol, 89(4), 1995: 698-703
9. IL-12 unmasks HLA class I differences during MLR induced IFN-γ production. M. Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. Hum Immunol, 44, 1995:145-155
10. Optimal control of IFN-γ and TNF-α by IL-10 produced in response to one HLA-DR mismatch during the primary mixed lymphocyte reaction. M.Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. Transplantation, 61, 1996:497-502
11. Regulation of IFN-γ during the mixed lymphocyte reaction. M.Toungouz, C. Denys, M. Andrien, E. Dupont. Transpl Proc, 28, 1996:2911-2912
12. Blockade of proliferation and TNF-α production occuring during the mixed lymphocyte reaction by IFN-γ specific natural antibodies contained in intravenous immunoglobulins (IVIg). M. Toungouz, C. Denys, E. Dupont. Transplantation, 62, 1996: 1292-1296 (Impact factor: 3.5)
13. Inhibition of IFN-g production by intravenous immunoglobulins during mixed lymphocyte reaction (MLR): consequences for proliferation and TNF-a production. M. Toungouz, C. Denys, E. Dupont. Transpl Proc, 29, 1997:1089
14. Optimal control of IFN-γ and TNF-α by IL-10 produced in response to one HLA-DR mismatch during the primary mixed lymphocyte reaction. M.Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. Transpl Proc, 29, 1997:1422
15. Increased in vitro immunosuppressive action of anti-CMV and anti-HBs intravenous immunoglobulins (IVIg) due to higher amounts of IFN-g specific neutralizing antibodies. C. Denys, M. Toungouz and E. Dupont. Vox Sanguinis, 72, 1997:247-250.
16. Comprehensive HLA matching. E. Dupont, M. Toungouz, M. Andrien, P. Vereerstraeten. Nephrology Dialysis and Transplantation, 12, 1997 :2048-2050
17. Cellular immunotherapy: a new avenue in internal medicine. M. Toungouz, T. Velu, K. Thielemans. Acta Clin Belg, 53, 1997 : 9-18
18. Remission and immune reconstitution after T cell depleted stem cell transplantation for rheumatoid arthritis. P. Durez, M. Toungouz, L. Schandene, M. Lambermont, M. Goldman. Lancet, 352, 1998 : 881-882
19. T-cell-depleted stem-cell transplantation for rheumatoid arthritis. P. Durez, M. Toungouz, A. Kentos, T. Appelboom and M. Goldman. The Lancet, 352, 1998: 1628-1629

20. Cell therapy: basis for new therapeutic strategies. M. Toungouz, M. Lambermont, T. Velu. Drug News and Perspectives, 12, 1999: 12-20
21. Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients. M. Toungouz, C. Quinet, E. Thille, S. Fourez, O. Pradier, J.P. Delville, T. Velu and M. Lambermont. Cytotherapy, 1, 1999: 447-453
22. Immunotherapy using dendritic cells. T. Velu, M. Toungouz, L. Faid, M. Libin, F. Lehmann, M. Laporte, P. Vereecken, D. Gangji, C. Bruyns, M. Lambermont, M. Goldman. European Cytokine Network 11: 306-308, 2000
23. Transplantation tolerance and mixed chimerism : at the frontier of clinical application. V. Donckier, M. Toungouz, M. Goldman. Transpl. Int. 14 :1-5, 2001
24. Hematopoietic stem cells : therapeutic applications in autoimmune diseases and in solid organ transplantation. M. Toungouz and M. Goldman. Adv. Nephrol. Necker Hosp., 31:257-272, 2001.
25. Transient expansion of peptide-specific lymphocytes producing IFN-g after vaccination with MAGE-A1/A3 positive tumors. M. Toungouz, M. Libin, F. Bulté, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, M. Goldman, T. Velu. J. Leuk. Biol., 69 : 937-943, 2001
26. Anti-tumor immunotherapy based on dendritic cells. M. Toungouz, M. Lambermont, T. Velu, C. Buelens, N. Vanderheyde, E. Bartholomé, F. Willems, D. Gangji, M. Goldman. J. Soc. Biol., 195 :19-23, 2001.
27. The immunology-hematology-transfusion department. M. Goldman, M. Andrien, JP Delville, E. Dupont, A. Kornreich, M. Lambermont, A. Ocmant, L. Schandené, F. Mascart, O. Pradier, P. Stordeur, M. Toungouz, W. Wijns. Rev Med Brux, 2002, 2: 87-91
28. ^{111}In and ^{99m}Tc-HMPAO labelling of antigen loaded dendritic cells: in vivo imaging and influence on motility and actin content. D. Blocklet, M. Toungouz, R. Kiss, M. Lambermont, T. Velu, M. Goldman, S. Goldman. European Journal of Nuclear Medicine, Eur J Nucl Med, 30:440-447, 2003
29. Tolerance induction in clinical tansplantation: the pending questions. M. Toungouz, V. Donckier, M. Goldman. Transplantation, 75 :58-60, 2003
30. Infusion of donor CD34+ bone marrow cells in cadaver kidney transplantation : clinical data. L. De Pauw, M. Toungouz and M. Goldman. Transplantation, 75 :46-49, 2003
31. Treatment of osteonecrosis of the femoral head with implantation of autologous bone-marrow cells : a pilot study. V. Gangji, JP Hauzeur, C. Matos, V. De Maertelaer, M. Toungouz, M. Lambermont. J Bone Joint Surg Am, 86:1153-1160, 2004
32. Donor stem cell infusion after non myeloablative conditioning for tolerance induction to HLA mismatched adult living-related liver graft. V. Donckier, R. Troisi, M. Toungouz, I. Colle, H. Van Vlierberghe, C. Jacky, P. Martiat, P. Stordeur, L. Zhou, N. Boon, M. Lambermont, L. Schandené, JL Van Laethem, L. Noens, M. Gelin, B. de Hemptinne, M. Goldman. Transplant Immunol., 13:139-146, 2004
33. New therapeutic approaches in melanoma. L.Mortier, P. Marchetti, L. Gordower, A.S. Charbonnier-Hatzfeld, M. Toungouz, T. Velu. Rev Med Brux, 25, 2004 :153-9.
34. Immune characterization of clinical grade dendritic cells generated from cancer patients and genetically modified by an ALVAC vector carrying MAGE minigenes. M. Trakatelli, M. Toungouz, Van der Bruggen O,

Lambermont M, Heenen M, Velu T, Bruyns C. Cancer Gene Therapy, 12:552-559, 2005

35. A rapid test to monitor alloreactive response in whole blood using real-time PCR. L. Zhou, M. Toungouz, M. Andrien, E. Dupont, M. Goldman, P. Stordeur. Transplantation, 80:410-413, 2005
36. IL-6 produced by type I IFN DC controls IFN-g production by blocking the suppressive effect of regulatory T cells. O. Detournay, N. Mazouz, M. Goldman and M. Toungouz. Human Immunol, 66:460-468, 2005
37. Immunostimulatory properties of human dendritic cells generated using IFN- associated with IL-3 or GM-CSF. N. Mazouz, O. Detournay, C. Buelens, J. Renneson, M. Trakatelli, , M. Lambermont, A. Marchant, M. Goldman, M. Toungouz. Cancer Immunol Immunother, 54:1010-1017, 2005
38. Stem cell therapy for the treatment of osteonecrosis. V. Gangji, M. Toungouz, J-P. Hauzeur. Expert Opin Biol Ther, 5:437-442, 2005
39. A new dendritic cell vaccine generated with interleukin-3 and interferon-induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. M. Trakatelli, M. Toungouz, D. Blocklet, Y. Dodoo, L. Gordower, M. Laporte, P. Vereecken, F. Sales, L. Mortier, N. Mazouz, M. Lambermont, S. Goldman, P. Coulie, M. Goldman, T. Velu. Cancer Immunol Immunother, 55:469-474, 2006
40. Myocardial homing of nonmobilized peripheral-blood CD34+ cells after intracoronary injection. D. Blocklet, M. Toungouz, G. Berkenboom, M. Lambermont, P. Unger, N. Preumont, E. Stoupel, D. Egrise, J.P. Degaute, M. Goldman, S. Goldman. Stem Cells, 24:333-336, 2006
41. Haematopoietic stem cell transplantation for severe autoimmune diseases: new perspectives. M. Toungouz Névessignsky, A .Ferster, Nephrology Dialysis and Transplantation, 21:1154-1157, 2006
42. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Donckier V, Troisi R, Le Moine A, Toungouz M, Ricciardi S, Colle I, Van Vlierberghe H, Craciun L, Libin M, Praet M, Noens L, Stordeur , Andrien M, Lambermont M, Gelin M, Bourgeois N, Adler M, de Hemptinne B, Goldman M. Liver Transplantation, 12 : 1523-1528, 2006
43. A rapid test of alloreactivity based on interleukin-2 mRNA expression might identify liver tranplant recipients with donor-specific hyporesponsiveness. L. Craciun, P. Stordeur, R. Troisi, A. Le Moine, M. Toungouz, I. Colle, H. Van Vlierberghe, P. Loi, V. Lucidi, B. de Hemtpinne, M. Goldman, V. Donckier. Transpl. Proc., 39:2665-7; 2007
44. Guidelines for the use of fresh frozen plasma. D. De Backer, B. Vandekerckhove, S. Stanworth, L. Williamson, C. Hermans, P. Van der Linden, R. Hubner, K. Jochmans, A. Ferrant, M. Lambermont, L. Muylle, M. Toungouz, Acta Clin Belg, 63:381-90, 2008.
45. Myocardial homing and coronary endothelial function after autologous blood CD34+ progenitor cells intracoronary injection in the chronic phase of myocardial infarction. C. Dedobbeleer, Didier Blocklet, M. Toungouz , M., P. Unger, J.P. Degaute, S. Goldman, G. Berkenboom· Journal Of Cardiovascular Pharmacology, 53:480-485, 2009
46. Human cystic fibrosis embryonic stem cell lines derived on placental mesenchymal stromal cells. Deleu S, Nguyen Thi M.U., Gonzalez-Merino E, Gaspard N, Vanderhaegen P, Toungouz M, Englert Y, Devreker F. Reproductive Biomedicine Online, 18:704-716, 2009
47. Mesenchymal stromal cells promote or suppress the proliferation of T

lymphocytes from cord blood and peripheral blood: importance of low cell ratio and the role of interleukine-6. M. Najar, R. Rouas, G. Raicevic, P. Lewalle, N. Meuleman, D. Bron, M. Toungouz, P. Martiat, L. Lagneaux. Cytotherapy 28 :1-14, 2009

48. Inflammation modifies the pattern and the function of TLR expressed by human mesenchymal stromal cells. G. Raicevic, R. Rouas, M. Najar, P. Stordeur, H. Id Boufker, D. Bron, M. Goldman, M. Toungouz Nevessignsky, L. Lagneaux. Human Immunology, 71:235-244, 2010.
49. MICA antibodies: sensitizing events and impact on renal graft outcomes. A. Lemy, M. Andrien, KM Wissing, K. Ryahi, A. Vandersarren, J. Racapé, C. Heylen, L. Ghysdal, N. Broeders, P. Vereerstraeten, M. Toungouz and D. Abramowicz. Transplantation, 90:168-174, 2010
50. Computer-aided HLA association studies: a case study for psoriasis and severe alopecia areata. D. Catanzaro, M. Andrien, M. Labbé, M. Toungouz Nevessignsky. Human Immunology, 71:783-8, 2010
51. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Najar M, Raicevic G, Id Boufker H, Stamatopoulos B, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Exp Hematol, 38:922-32, 2010
52. Adipose tissue and Wharton's Jelly derived msenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Najar M, Raicevic G, Id Boufker H, Fayyad Kazan H, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Tissue Eng Part A, 11:3537-46
53. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Najar M, Raicevic G, Boufker HI, Kazan HF, Bruyn CD, Meuleman N, Bron D, Toungouz M, Lagneaux L. Cell Immunol 264:171-9, 2010
54. Bortezomib: a new player in pre- and post-transplant desensitization? A. Lemy, M. Toungouz, D. Abramowicz. Nephrology Dialysis and Transplantation 25:3480-9, 2010
55. The Source Of Human Mesenchymal Stromal Cells Influences their TLR profile as well as Their Functional Properties. Raicevic G, Najar M, Stamatopoulos B, De Bruyn C Meuleman N, Bron D, Toungouz M, Lagneaux L. Cell. Immunol. 270(2), 207-216, 2011
56. Inflammation and TLR ligation affect the osteogenic potential of human mesenchymal stromal cells (MSC) depending on their tissue origin. Raicevic G, Najar M, Pieters K, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Tissue Engineering, 18(13-14):1410-8, 2012
57. Posttransplant major histocompatibility complex class I chain-related gene A antibodies and long term graft outcomes in a multicentre cohort of 779 kidney transplant recipients. Lemy A, Andrien M, Labalette M, Noel C, Hiesse C, Delahousse M, Suberbielle-Boissel C, De Meyer M, Latinne D, Mourad M, Delsaut S, Racapé J, Wissing KM, Toungouz M, Abramowicz D. Transplantation, 93(12):1258-64, 2012.
58. Strategies to work with HLA data in human populations for histocompatibility, clinical transplantation, epidemiology and population genetics: HLA-NET methodological recommendations. Sanchez-Mazas A, Vidan-Jeras B, Nunes JM, Fischer G, Little AM, Bekmane U, Buhler S, Buus S, Claas F, DormoyA, Dubois V, Eberhard HP, Eglite E, Gonzalez-Galarza F, Grubic Z, Ivanova M, Lie B, Ligeiro D, Lokki MJ, Maldonado Torres H Marsh SGE, Martins da Silva B, Martorell J,

Mendonça D, Middleton D, Muller CH, Papasteriades C, Poli F, Riccio ME, Spyropoulou Vlachou M, Sulcebe G, Tonks S, Toungouz Nevessignsky M, Vangenot C, van Walraven AM and Tiercy JM. Int J Immunogenetics, 39(6): 459-472 , 2012

59. Characterization and functionality of the CD200-CD200R system during mesenchymal stromal cell interactions with T-lymphocytes. Najar M, Raicevic G, Jebbawi F, De Bruyn C, Meuleman N, Bron D, Toungouz M, Lagneaux L. Immunol Lett, 146(1-2):50-6, 2012.
60. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the exrpression and impact of inflammatory priming. Najar M, Raicevic G, Fayyad-Kazan H, De Bruyn C, Bron D, Toungouz M and Lagneaux L. Stem Cell Rev, 8(4):1286, 2012.
61. Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and migration. Najar M, Raicevic G, Fayyad-Kazan H, De Bruyn C, Bron D, Toungouz M and Lagneaux L. Int Immunopharmacol, 15(4):693-702, 2013
62. The HLA-net Gene(Rate) pipeline for effective HLA data analysis and its application to 145 population samples from Europe and neughbouring areas. Nunes JM, Buhler S, Roessli D, Sanchez-Mazas A and the HLA-net collaboration. Tissue Antigens, 83:307-323, 2014
63. Bone Marrow Mesenchymal Stromal Cells induce proliferative, cytokine and molecular changes during the T cell response: the importance of the IL-10/CD210 axis. Najar M; Raicevic G, Fayyad-Kazan H, De Bruyn C, Bron D, Toungouz M, Lagneaux L. Stem Cell Rev, 11:442-452, 2015
64. Influence of inflammation on the immunological profile of adult derived human liver mesenchymal stem cells and stellate cells. Raicevic G, Najar M, Najimi M, El Taghdouini A, van Grunsven L A, Sokal E, Toungouz M. Cytotherapy, 17:174-185, 2015.
65. Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. Cytotherapy, 18:160-171, 2016
66. The immunomodulatory potential of mesenchymal stromal cells: a story of a regulatory network. Najar M, Raicevic G, Crompot E, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L. J Immunother. 39:45-59, 2016.
67. Mesenchymal stromal cells from the forsekin: tissue isolation, cell characterization and immunobiological properties. Najar M, Raicevic G, André T, Fayyad-Kazan H, Pieters K, Bron D, Toungouz M, Lagneaux L. Cytotherapy, 18:320-335, 2016.
68. Human leucocytes (HLA) class I and II typing in Belgian multiple sclerosis patients. A. Lysandropoulos, J. Racapé, V. Holovska, M. Toungouz. Acta neurologica belgica, 117 :61-65, 2017
69. Human hepatic stellate cells and inflammation: a regulated cytokine network balance. M. Najar, Fayyad-Kazan H, Faour WH, El Taghdouini A., Raicevic G, Najimi M, Toungouz M, van Grunsven LA, Sokal E, Lagneaux L. Cytokine, 90:130-134, 2017
70. Comparison and immunobiological characterization of retinoic acid inducible gene-I-like receptor expression in mesenchymal stromal cells. Raicevic G, Najar M, Busser H, Crompot E, Bron D, Toungouz M, Lagneaux L. Sci Reports, 7:2896-2900, 2017
71. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 : the Donated Antibodies Working against nCov (DAWn-Plasma) trial. Devos T, Geukens T, Barbezange C., Cleeren M.n Compernolle V., Dauby N., Desmecht D., Grimaldi D., Lambrecht B., Luyten A., Maes P,. Mouyschen M., Romano M., Seyler L., Toungouz

Névessignsky M., Vandenberghe K., Vlieghe E., Yombi J.C., Liesenborgh L., Verhamme P., Meyfroidt G. Trials, 21 :981, 2020

72. International Forum on the collection and use of COVID-19 convalescent plasma: protocols, challenges and lessons learned: summary. Arwa Z Al-Riyami, Thierry Burnouf, Mark Yazer, Darrell Triulzi , Levent Tufan Kumaş, Levent Sağdur, Nil Banu Pelit , Renée Bazin, Salwa I Hindawi, Maha A Badawi, Gopal K Patidar, Hem Chandra Pandey, Rahul Chaurasia, Roberta Maria Fachini, Patrícia Scuracchio Silvano Wendel, Ai Leen Ang, Kiat Hoe Ong , Pampee Young , Jarkko Ihalainen, Antti Vierikko, Yan Qiu, Ru Yang, Hua Xu, Naomi Rahimi-Levene , Eilat Shinar , Marina Izak , Carlos Alberto Gonzalez , David Martin Ferrari , Paula Verónica Cini , Robby Nur Aditya, Ratti Ram Sharma [21], Suchet Sachdev [21], Rekha Hans [21], Divjot Singh Lamba [21], Lise Sofie H Nissen-Meyer , Dana V Devine , Cheuk Kwong Lee , Jennifer Nga-Sze Leung , Ivan Fan Ngai Hung , Pierre Tiberghien , Pierre Gallian , Pascal Morel , Khuloud Al Maamari , Zaid Al-Hinai , Hans Vrielink , Cynthia So-Osman , Vincenzo De Angelis , Pierluigi Berti , Angelo Ostuni , Giuseppe Marano , Michel Toungouz Nevessignsky , Magdy El Ekiaby , James Daly , Veronica Hoad , Sinyoung Kim , Karin van den Berg , Marion Vermeulen [34], Tanya Nadia Glatt , Richard Schäfer , Rita Reik , Richard Gammon , Melissa Lopez , Lise Estcourt , Sheila MacLennan , David Roberts , Vernon Louw , Nancy Dunbar, ISBT Convalescent Plasma Group. Vox Sang, 116: 1117-1135, 2021
73. International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses. Arwa Z Al-Riyami, Thierry Burnouf, Mark Yazer, Darrell Triulzi , Levent Tufan Kumaş, Levent Sağdur, Nil Banu Pelit , Renée Bazin, Salwa I Hindawi, Maha A Badawi, Gopal K Patidar, Hem Chandra Pandey, Rahul Chaurasia, Roberta Maria Fachini, Patrícia Scuracchio Silvano Wendel, Ai Leen Ang, Kiat Hoe Ong , Pampee Young , Jarkko Ihalainen, Antti Vierikko, Yan Qiu, Ru Yang, Hua Xu, Naomi Rahimi-Levene , Eilat Shinar , Marina Izak , Carlos Alberto Gonzalez , David Martin Ferrari , Paula Verónica Cini , Robby Nur Aditya, Ratti Ram Sharma [21], Suchet Sachdev [21], Rekha Hans [21], Divjot Singh Lamba [21], Lise Sofie H Nissen-Meyer , Dana V Devine , Cheuk Kwong Lee , Jennifer Nga-Sze Leung , Ivan Fan Ngai Hung , Pierre Tiberghien , Pierre Gallian , Pascal Morel , Khuloud Al Maamari , Zaid Al-Hinai , Hans Vrielink , Cynthia So-Osman , Vincenzo De Angelis , Pierluigi Berti , Angelo Ostuni , Giuseppe Marano , Michel Toungouz Nevessignsky , Magdy El Ekiaby , James Daly , Veronica Hoad , Sinyoung Kim , Karin van den Berg , Marion Vermeulen [34], Tanya Nadia Glatt , Richard Schäfer , Rita Reik , Richard Gammon , Melissa Lopez , Lise Estcourt , Sheila MacLennan , David Roberts , Vernon Louw , Nancy Dunbar. Vox Sang, 116:e71-e120, 2021.
74. Early and out-of-hospital use of COVID-19 convalescent plasma: an international assessment of utilization and feasibility. Al-Riyami AZ, Estcourt L, Rahimi-Levene N, Bloch EM, Goel R, Tiberghien P, Thibert JB, Bruun MT, Devine DV, Gammon RR, Wendel S, Toungouz Nevessignsky M, Grubovic Rastvorceva RM, Oreh A, Romon I, van den Berg K, Kitazawa J, Patidar G, So-Osman C, Wood EM; ISBT COVID-19 Convalescent Plasma Working Group. Vox Sang, 117(10):1202-1210, 2022
75. The use of predictive modelling to determine the likelihood pf donor return during the COVID-19 pandemic. Gammon R , Hindawi S, Al-Riyami, AZ, Ang A, Bazin R, Bloch EM, Counts K, de Angelis V, Goel R, Grubovic R, Pati I, Lee CK, La Raja M, Mengoli C, Oreh A, Patidar

GK, Rahimi-Levene, N, Ravula U, Rexer K, So-Osman C, Tchachil J, Toungouz Nevessignsky M, Vermeulen M. .Tranfusion Medicine, 34(5): 333-343, 2024

Projects

-CLINICOBRU : « Creation of an interuniversity clinical research platform in Brussels» funded by INNOVIRIS ; interuniversity ULB-VUB-UCL ; 1-1-2012 to 31-12-2015

-BRUSTEM 2 : « Regenerative medicine of the liver using synergistic mixture of immature or mature hepatocytes with mesenchymal stem or progenitor cells or with hepatic stellar cells"; funded by INNOVIRIS; interuniversity ULB-VUB-UCL, 1-6-2011 to 31-5-2014

-COST ACTION BM0803: "HLA molecular data in epidemiology, transplantation and population genetics", European COST Action; international (22 countries); 1-6-2008 to 31-1-2013

-BRUSTEM 1 : « Regenerative medicine of the liver using synergistic mixture of immature or mature hepatocytes with mesenchymal stem or progenitor cells or with hepatic stellar cells"; INNOVIRIS; interuniversitaire ULB-VUB-UCL; 1-6-2009 to 31-5-2011; budget: 1.360.930 €

Memberships

AWARDS:

-« European Cytokine Student Award », European Cytokine Society (1999)

-« Fernand De Waele » prize, FNRS, Belgium (1999)

Oral communications:

1. Are antiphospholipid antibodies induced by cerebral ischemia? M. Toungouz, S. Blecic, A. Liart, C. Kucharzewski, P. Capel. Surface Mediated Hemostatic Processes, the FRSM/FGWO Coagulation Contact Group, K.U.Leuven Gasthuisberg, Leuven, Belgium, 13 december 1991.
2. Increased release of monokines IL-6 and TNF-αby lipopolysaccharide after alloactivation induced by HLA class II differences on leucocytes. M. Toungouz , C. Denys, D. De Groote, M. Andrien, E. Dupont. Belgian Hematological Society, Brussels, Belgium, 6 february 1993, best abstract.
3. Alloactivation induced during MLR by HLA class II differences induces release by macrophages of tumor necrosis factor- and interleukin-6 and primes them to lipopolysaccharides. M. Toungouz, C. Denys, D. De Groote, M. Andrien, E. Dupont. European Foundation for Immunogenetics, Stresa, Italy, 19-21 march 1993.
4. Cytokines release during MLR. M. Toungouz HLA club meeting. Leiden, The Netherlands, 9 december 1993.
5. Modulation of HLA-DR mediated cytokines production by intravenous immunoglobulins (IVIg). M. Toungouz, C. Denys and E. Dupont. Belgian Hematological Society, Brussels, Belgium, 28-29 January 1994.
6. Variations of DR4 polymorphism detected at the DNA level induce IL-6 and TNF production during MLR. M. Toungouz, C. Denys, M. Andrien, E. Dupont. European Foundation for Immunogenetics, Strasbourg, France, 7-9 march 1994; Belgian Transplantation Society, Brussels, Belgium, 5 march 1994.
7. Inhibition of HLA-DR mediated cytokines production by intravenous immunoglobulins. M. Toungouz, C. Denys and E. Dupont. European Haematology Association, Brussels, Belgium, 2-5 june 1994.

8. HLA-DR subtypes induce IL-6 and TNF- production in the primary mixed lymphocyte reaction. M. Toungouz, C. Denys, M. Andrien, E. Dupont. XVth World Congress of the Transplantation Society. Kyoto, Japan, 28 august-2 september 1994.
9. IFN-γproduction during mixed lymphocyte reaction. M. Toungouz. HLA club meeting. Maastricht, The Netherlands, 8 december 1994.
10. IL-12 unmasks HLA class I differences during MLR induced IFN-γ production. M. Toungouz, C. Denys, M. Van der Cruys, M. Andrien, D. De Groote, and E. Dupont. European Foundation for Immunogenetics/British Society for Histocompatibility and Immunogenetics Joint Meeting, Brighton, Angleterre, 8-11 march 1995; Belgian Transplantation Society, Antwerpen, Belgium, 4 march 1995.
11. HLA class I differences induce IL-12 dependent IFN-γrelease during mixed lymphocyte reaction. M. Toungouz, C. Denys, D. De Groote, M. Andrien and E. Dupont. American Society for Histocompatibility and Immunogenetics, 21st Annual Meeting, Dallas, USA, 6-11 october 1995.
12. Optimal control of IFN-γand TNF-αby IL-10 produced in response to one HLA-DR mismatch during the primary mixed lymphocyte reaction. M.Toungouz, C. Denys, M. Andrien, D. De Groote, E. Dupont. 12th International Histocompatibility Workshop and Conference Saint-Malo/Paris, France, 4-12 june 1996.
13. HLA mismatches and cytokines induction. M. Toungouz. Third tutorial on histocompatibility, Leiden, The Netherlands, 14-15-16 November 1996.
14. G-CSF mobilization decreases the ability of T-lymphocytes to produce Th1 type cytokines in humans. A. Kornreich, M. Lambermont, W. Feremans, D. Bron, O. Pradier, M. Goldman and M. Toungouz. The International Society for Hematotherapy and Graft Engineering (ISHAGE), 3rd international meeting, Bordeaux, France, 31 may- 3 june, 1997.
15. Decreased IFN- secretion by T lymphocytes in leukapheresis after G-CSF mobilization of healthy donors. A. Kornreich, M. Lambermont, W. Feremans, D. Bron, O. Pradier, M. Goldman and M. Toungouz. American Society of Hematology, 39th annual meeting, San Diego, California, USA, 5-9 decembrer 1997.
16. Cell therapy : a challenge for the future (plenary session). M. Toungouz. Journées de Transfusion – Dagen van de bloedtransfusie, Liège, 6-7 march 1998.
17. Monitoring of anti-MAGE T cell responses by cytokine flow cytometry and ELISPOT after dendritic cell-based vaccination. M. Toungouz, M. Libin, M. Lambermont, P. van der Bruggen, T. Boon, M. Goldman, T. Velu. 4th European Winter Conference in Immunology : « The Saint-Sorlin Workshop », Saint-Sorlin d'Arves, France, 19-22 January 1999.
18. The role of cytokines in alloreactivity (Educational Programme). M. Toungouz. 14th General meeting of the Belgian Hematological Society. Genval, Belgium, 19-20 february 1999.
19. High expression of HLA-DR, co-stimulatory and adhesion molecules at the surface of clinical grade dendritic cells from cancer patients. M. Toungouz, J.-P. Delville, O. Pradier, M. Lambermont and E. Dupont. 13th European Histocompatibility Conference, Aghia Pelaghia, Crête, Greece, 13-17 april 1999.
20. Generation of autologous clinical grade dendritic cells pulsed with MAGE peptides for vaccination of cancer patients. M. Toungouz, C. Quinet, E. Thille, S. Fourez, J.P. Delville, O. Pradier, T. Velu and M. Lambermont. International Society for Hematotherapy and Graft Engineering (ISHAGE), Oslo, Norway, 30 Mai – 1st june 1999.
21. Generation of immature autologous clinical grade dendritic cells for

vaccination of cancer patients. M. Toungouz, C. Quinet, E. Thille, S. Fourez, M. lambermont. Club francophone des cellules dendritiques. Paris, France, 14-15 december 1999.

22. Immunotherapy using dendritic cells. T. velu, M. Toungouz, L. Faid, M. Libin, F. Lehmann, M. Laporte, P. Vereecken, D. Gangji, C. bruyns, M. Lambermont, M. Goldman. Euroconférence de l'Institut Pasteur "Thérapie Cellulaire", Paris, France, 3-4 february 2000.
23. Chimérisme et tolérance. M. Toungouz. Ateliers francophones de transplantation - Groupe de Venise. Sevilla, Spain, 31 march- 1st april 2000.
24. Tolerance induction in organ transplantation. M. Toungouz. "Interest of ATG in the adjustment of new HSCT strategies", réunion organisée par l'Universita degli studi di Firenze, Istituto di clinica medica generale e cardiologia. Artimino, Italy, 26 october 2000.
25. Peptide-specific lymphocytes producing IFN- and IL-5 are expanded by vaccination with dendritic cells pulsed with MAGE peptide, followed by systemic IL-2 administration, in patients with MAGE-positive tumors. M. Toungouz, L. Faid, D. Duriau, V. Olislagers, F. Lehmann, M. Laporte, P. Vereecken, D. Van Gansbeke, C. Bruyns, M. Lambermont, M. Goldman, T. Velu. ABEC-BVSK (Belgian association for cancer research), Brussels, Belgium, 20 january 2001.
26. Immunothérapie anti-tumorale utilisant les cellules dendritiques en tant qu'adjuvant naturel. M. Toungouz. Journée thématique de l'Institut Albert Bonniot, Université de Grenoble, Grenoble, France, 11 may 2001.
27. Use of dendritic cells genetically modified by ALVAC vectors carrying MAGE sequences to induce anti-melanoma immune responses. Trakatelli M, Toungouz M, van der Bruggen P, Lambermont M, Velu T, Heenen M, Bruyns C. Guest Lecture « Jean Thivolet », Congrès annuel de la recherche dermatologique (CARD) de la Société de Recherche Dermatologique (SRD), Brussels, Belgium, 10-12 may 2001.
28. Induction of IFN-g and cytokine producing cells after dendritic cell based vaccination in cancer patients. M. Toungouz Névessignsky. International Symposium « Interferon and cytokines », Habana, Cuba, 2-5 december 2001.
29. Donor derived stem cells in organ transplantation. M. Toungouz. Euroconference IV, Immunobiology and immunogenetics of transplantation: from basic to clinical sciences. Institut d'Hématologie, Paris, France, 13-15 december 2002.
30. Immune monitoring in whole blood using real time PCR. Zhou L, Toungouz M, De Groote D, Palmantier R, Velu T, Goldman M, Stordeur P. Atelier du Club Francophone des Cellules Dendritiques, Paris, France, 16 december 2002.
31. Anti-tumoral vaccination with dendritic cells. M. Toungouz. IXth Belact meeting, 21 march 2003, Brussels, Belgium
32. Donor-specific hyporesponsiveness and immunosuppression withdrawal after living related HLA-mismatched liver transplantation preceded by hematopoietic stem cell allograft. M. Toungouz, V. Donckier, R. Troisi, I. Colle, H. Van Vlierberghe, M. Gelin, B. de Hemtpinne, M. Lambermont, M. Goldman. Tenth NAT (Nantes Actualités Transplantation), « Stem cells and transplantation », 19-20 june 2003, Nantes, France.
33. Importance du typage HLA dans les greffes non familiales. M. Toungouz, 13 février 2004, « 20 ans de greffes allogéniques à l'Institut Jules Bordet ».
34. Immunosuppression withdrawal after myeloconditioning and donor stem cells infusion in living donor transplantation : a pilot study. R. Troisi, V. Donckier, S. Ricciardi, I. Colle, H. Van Vlierberghe, M. Toungouz, L.

Noens, A. Le Moine, M. Goldman, B. De Hemptinne. The third international congress on immunosuppression. San Diego, California, USA, 8-11 December 2004.

35. A randomized phase I/II trial of antitumor vaccination using the recombinant MAGE-A3 protein loaded on myeloid DC or mixed with the adjuvant AS02B in melanoma patients. L. Gordower, M. Toungouz, V. Richard, R. Palmantier, M. Trakatelli, V. Vantomme, M. Lambermont, V. Brichard, M. Goldman, T. Velu. Orlando, Florida, USA, 13-17 may 2005.
36. IL-6 produced by type I IFN DC controls IFN-g production by regulating the suppressive effect of CD4+CD25+ regulatory T cells. O. Detournay; M. Mazouz, M. Goldman, M. Toungouz. 20th European Federation for Immunogenetics Conference, Oslo, Norway, 8-11 june 2006.
37. Inflammation modifies the pattern and the function of TLR expressed by human mesenchymal stromal cells. G. Raicevic, R. Rouas, P. Stordeur, M. Najar, H. Id Boufker, D. Bron, P. Martiat, M. Goldman, M. Toungouz, L. Lagneaux. Annual Meeting of the International Society for Cell Therapy, Miami, FL, USA, May 17-22 2008.
38. MICA antibodies in a cohort of 1091 uremic patients and controls: triggering factors and determination of auto- or allo-specificity. A. Lemy, M., A. Vandersarren, K.M. Wissing, K. Ryhahi, L. Ghisdal, N. Broeders, P. Vereerstraeten, M. Toungouz, D. Abramowicz. 23rd European Immunogenetics and Histocompatibility Conference, Ulm, Germany, 9-12 mai 2009.
39. Mathematical models for HLA association studies: A case study for psoriasis and severe alopecia Areata. Daniele Catanzaro, Marc Andrien, Martine Labbé, Michel Toungouz Nevessignsky. 23rd European Immunogenetics and Histocompatibility Conference, Ulm, Germany, 9-12 mai 2009.
40. Inoculation in children: immune responses in high risk patients with/after chronic immunosuppression. Michel Toungouz Nevessignsky, CHMP/PDCO/CMDh European Medicine Agency – Polish Presidency joint meeting, Warsaw 29-30, Poland, septembre 2011.
41. Influence of the microenvironment on the immunosuppressive and regenerative properties of mesenchymal stromal cells. Michel Toungouz Névessignsky, International Conference, “Stem cells and regenerative medicine”, Uppsala, Sweden, 28-29 novembre 2011.
42. The emergence of academic research organizations in Europe: ClinicoBRU, the Brussels Platform Model. Michel Toungouz and Marc Tomas, Biopartnering Future Europe, Brussels, Belgium, October 9-10 2012
43. “The Belgian registry of bone marrow donors” Michel Toungouz Névessignsky, HLA-NET symposium “Anthropological aspects of bone marrow donor registries”, 30-31 october 2012, Nicosie Cyprus.
44. « Influence des TLR et de l’inflammation sur la fonction des cellules stromales mésenchymateuses isolées à partir de différentes sources », Michel Toungouz, Laurence Lagneaux et Gordana Raicevic. Journées scientifiques de la Société Francophone d’Histocompatibilité et d’Immunogénétique (SFHI), Paris,France, 23-24 January 2013.
45. « Mesenchymal Stromal Cells and Immunogenetics of Cancer ». Michel Toungouz, First School of Immunogenetics, Faculty of Sciences, Rabat, Morocco, 2-6 October 2013.
46. « Immunogenetics of cancer », Michel Toungouz, Vth annual meeting of the Moroccan Society of Immunology, Rabat, Morocco, 7-8 October 2013
47. “Autologous osteoblastic cells (PREOB®) versus concentrated bone marrow implantation in osteonecrosis of the femoral head: a randomized

study". J. P. Hauzeur, M. Toungouz, C. Lechanteur, Y. Beguin, E. Baudoux, V. De Maertelaer, P. Sanjiva, R. Katz, J. Ino, D. Egrise, M. Malise, V. Gangji, SOFCOT (Société Française de Chirurgie Orthopédique et Traumatologique) 2016, Paris, France, 8-11 November 2016.

48. « Autologous osteoblastic cells (PREOB ®) versus concentrated bone marrow implantation in osteonecrosis of the femoral head : a randomized controlled single blind study ». V. Gangji, M. Toungouz, C. Lechanteur, Y. Beguin, E. Baudoux, V. De Maertelaer, S. Pather, R. Katz, J. Ino, D. Egrise, M. Malaise, J.P. Hauzeur ». American Society for Bone and Mineral Research, annual meeting, Atlanta, Georgia, USA, 8-11 september 2016.
49. « Autologous osteoblastic cells (PREOB ®) versus concentrated bone marrow implantation in osteonecrosis of the femoral head : a randomized controlled single blind study ». V. Gangji, M. Toungouz, C. Lechanteur, Y. Beguin, E. Baudoux, V. De Maertelaer, S. Pather, R. Katz, J. Ino, D. Egrise, M. Malaise, J.P. Hauzeur ». EULAR (European League Against Rheumatism) 2016, London, Great Britain, 8-11 june 2016.
50. « Le matériel corporel humain (MCH) : des enjeux aux applications ». M. Toungouz, Yvoir, Belgium, 25 May 2019
51. « Therapeutic potential of stem cells and biomaterials in orthopedic surgery ». M. Toungouz Névessignsky, Orthopedica Belgica Fall Course 2018, Brussels, Belgium, 24 November 2018
52. « Perspectives des banques de tissus appliquées à l'appareil locomoteur ». M. Toungouz Névessignsky, SOFOP 2019, Brussels, Belgium, 13-15 march 2019

Other Relevant Information